← All trials
NCT05216328
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 2, 2022
- Primary completion
- Aug 31, 2024
- Completion date
- Oct 31, 2024
- First posted
- Jan 31, 2022
- Last posted
- Dec 5, 2022
- Enrollment
- 330
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Free University of AmsterdamLead sponsor
- Jeroen Bosch ZiekenhuisCollaborator
- Radboud UniversityCollaborator
- Rijnstate HospitalCollaborator
- University of GroningenCollaborator
- Utrecht UniversityCollaborator
- Leiden UniversityCollaborator
- Free University of AmsterdamOverall official - principal investigator
- Free University of AmsterdamReponsible party - principal investigator
- Erasmus University RotterdamCollaborator
- Spaarne GasthuisCollaborator
- FlevoziekenhuisCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.